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Background: There is increasing concern that prescription stimulants may be associated with adverse
cardiovascular events such as stroke, myocardial infarction, and sudden death. Public health concerns are amplified
by increasing use of prescription stimulants among adults.
Methods: The objective of this study was to conduct a systematic review of the evidence of an association
between prescription stimulant use and adverse cardiovascular outcomes. PUBMED, MEDLINE, EMBASE and Google
Scholar searches were conducted using key words related to these topics (MESH): ADHD; Adults; Amphetamine;
Amphetamines; Arrhythmias, Cardiac; Cardiovascular Diseases; Cardiovascular System; Central Nervous Stimulants;
Cerebrovascular; Cohort Studies; Case–control Studies; Death; Death, Sudden, Cardiac; Dextroamphetamine; Drug
Toxicity; Methamphetamine; Methylphenidate; Myocardial Infarction; Stimulant; Stroke; Safety. Eligible studies were
population-based studies of children, adolescents, or adults using prescription stimulant use as the independent
variable and a hard cardiovascular outcome as the dependent variable.
Results: Ten population-based observational studies which evaluated prescription stimulant use with cardiovascular
outcomes were reviewed. Six out of seven studies in children and adolescents did not show an association
between stimulant use and adverse cardiovascular outcomes. In contrast, two out of three studies in adults found
an association.
Conclusions: Findings of an association between prescription stimulant use and adverse cardiovascular outcomes
are mixed. Studies of children and adolescents suggest that statistical power is limited in available study
populations, and the absolute risk of an event is low. More suggestive of a safety signal, studies of adults found an
increased risk for transient ischemic attack and sudden death/ventricular arrhythmia. Interpretation was limited due
to differences in population, cardiovascular outcome selection/ascertainment, and methodology. Accounting for
confounding and selection biases in these studies is of particular concern. Future studies should address this and
other methodological issues.Background
There has been increasing concern that prescription
stimulant use may be linked to adverse cardiovascular
events such as sudden death, myocardial infarction, and
stroke. Scrutiny has increased, in part, due to the bur-
geoning use of prescription stimulants among adults [1-
3]. Older adults using prescription stimulants [4] may be* Correspondence: arthur.westover@utsouthwestern.edu
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distribution, and reproduction in any mediumparticularly vulnerable to adverse cardiovascular events,
given their higher background rate of cardiovascular
events and comorbid conditions, higher doses of stimu-
lants [2,5], and slower drug elimination [6].
Prescription stimulants are primarily used in the treat-
ment of attention deficit hyperactivity disorder (ADHD),
but also for obesity [7] and narcolepsy [8] as well as “off-
label” indications such as depression [9], stroke rehabili-
tation [10], and traumatic brain injury [11]. Stimulants
act by blocking reuptake of norepinephrine and dopa-
mine as well as increasing their release into the extracel-
lular space [12]. Stimulants may cause adverseCentral Ltd This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and heart rate [13-17], 2) inducing vasospasm through
increased levels of circulating catecholamines [18-27], 3)
causing vasculitis by inducing formation of circulating
proinflammatory immunoactive gylcation end products
[19,28-38], and 4) prolonging the cardiac QT interval,
which is associated with torsades de pointes [39-41].
The cardiovascular epidemiological literature has shown
that even modest increases in blood pressure have been
associated with increased risk of adverse cardiovascular
events [42-45]. Prescription stimulants have been linked
to adverse cardiovascular events in case reports [24-
26,35,46-49].
Safety concerns have impacted governmental regula-
tory policy. In 2006, the US Food and Drug Administra-
tion (FDA) issued a class-specific warning for
prescription stimulants regarding potentially increased
risk of adverse cardiovascular events [50]. In 2008, the
American Heart Association (AHA) published a scien-
tific statement on the use of prescription stimulants in
children and adolescents [51]. It recommended obtain-
ing a careful history and performing a physical exam
prior to initiating stimulants. Reflecting the prevailing
uncertainty about cardiovascular safety, the guideline
was non-committal regarding the need for a pre-treat-
ment electrocardiogram. Nor did the AHA statement
specify any absolute contraindications to use of stimu-
lants, including the presence of structural heart disease.
Nor did they address prescription stimulant use in
adults—the population presumably at the highest risk of
adverse outcomes. Subsequently, the American Academy
of Pediatrics (AAP) recommended not routinely obtain-
ing electrocardiograms in children in a 2008 policy state-
ment [52]. The AAP and AHA released a consensus
statement later in 2008 that described obtaining an ECG
prior to initiating stimulant therapy as reasonable but
not mandatory, and that treatment should not be with-
held on the basis of not having obtained an ECG [53].
Conversely, Health Canada recommended avoiding
stimulant use in patients with symptomatic cardiovascu-
lar disease and known structural cardiac abnormalities
[54]. Since then screening of children initiated on stimu-
lants by non-cardiologists and cardiologists increased in
Canada and the US [55,56]. Australian draft guidelines
on ADHD completed in 2009 recommended assessment
of cardiac risk factors prior to initiating stimulant use.
But these guidelines remain unapproved due to concerns
about the scientific integrity of some referenced studies
[57].
Recently, two prescription stimulants have fallen under
strict US regulatory scrutiny. Sibutramine, a compound
marketed as an appetite suppressant and closely related
to the amphetamine-family, was withdrawn from the US
market in October 2010 by its manufacturer AbbottLaboratories, at the request of the FDA [58]. An
increased risk of adverse cardiovascular events (16%)
was weighed against modest weight loss. Qnexa, a com-
bination of topiramate and the stimulant phentermine,
failed to achieve FDA approval in 2010 for the treatment
of weight loss due in part to concerns about cardiovas-
cular risk [59]. This was despite its clear efficacy in
weight loss. In a reversal, an FDA advisory committee
voted overwhelmingly to recommend approval of the
drug, persuaded in part that the benefit of treating obes-
ity outweighs the risk of adverse events [60].
Rationale
Only recently have observational studies begun to ad-
dress whether prescription stimulants are associated
with adverse cardiovascular events. Providers, patients,
and policy makers need clearer guidance on the best
way to balance potential benefits and harms of these
rapidly increasingly used medications.
Objective
The aim of this study was to systematically review popu-
lation-based studies of children and adults that tested
the association between exposure to prescription stimu-
lants and adverse cardiovascular outcomes. Methodo-
logical challenges that face the field and suggestions for
future directions of research are described.
In this review, “prescription stimulants” refer to pre-
scribed medications in the amphetamine-family of drugs,
namely comprised of amphetamine, methylphenidate,
methamphetamine and their variants. Sometimes stimu-
lants are referred to in the plural as “amphetamines” (as




For the systematic review, studies were considered using
the following criteria: 1) retrospective or prospective
population-based study, 2) children or adults as partici-
pants, 3) prescription stimulant use as the independent
variable, and 4) one or more hard cardiovascular out-
comes as the dependent variable and primary outcome.
Blood pressure, pulse, and EKG changes—established
physiological effects of stimulants—were not considered
hard clinical events. PUBMED, MEDLINE, EMBASE,
and Google Scholar databases were searched for studies
published in English in peer-reviewed journals between
January 1, 1990 and April 1, 2012 using MESH terms
and keywords: ADHD; Adults; Amphetamine; Ampheta-
mines; Arrhythmias, Cardiac; Cardiovascular Diseases;
Cardiovascular System; Central Nervous Stimulants;
Cerebrovascular; Cohort Studies; Case–control Studies;
Death; Death, Sudden, Cardiac; Dextroamphetamine;
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Myocardial Infarction; Stimulant; Stroke; Safety. In
addition, we hand-searched potentially relevant studies
cited in the reference section of electronically identified
articles. Titles and abstracts were screened for inclusion/
exclusion, and full text versions were retrieved. Selected
population-based studies of children were categorized
separately from studies of adults for the purpose of com-
parisons. Studies were assessed for bias at both the study
and outcome levels. Catchment, comparison groups, ex-
posure and outcome ascertainment, statistical power and
methodologies were assessed.Results
Population-based observational studies of prescription
stimulant use
Overall, 551 unique records were identified in searches.
Most records were excluded based on review of titles
and abstracts due to not being topical to prescription sti-
mulants and not having appropriate endpoints. Twenty-
seven full-text articles were assessed for eligibility. Most
(14) were eliminated due to lack of hard cardiovascular
endpoints. Ten studies met the inclusion criteria and
were included in the qualitative synthesis (Figure 1).
These studies, using large population-based datasets spe-
cifically designed to detect a signal of cardiovascular
harm associated with medical use of stimulants, found
mixed results (Table 1).Figure 1 Systematic Review Flowchart.Children and adolescents
In Winterstein et al.’s study of 55,383 Florida Medicaid
beneficiaries, 3 to 20 years old, no increase in cardiac
death or hospitalizations was observed [61]. However,
there was a 20% increased risk in cardiac-related emer-
gency room visits among current users of stimulants. A
second study by Winterstein et al., compared the risk
between methylphenidate and amphetamine salt medica-
tion preparations [62]. In 2,131,953 Florida Medicaid
beneficiaries, 3 to 20 years old, no difference was found
in risk of emergency room visits for cardiac reasons be-
tween the two medication groups.
McCarthy et al. studied a UK database of patients, 2 to
21 years old, who were prescribed methylphenidate, dex-
amphetamine, or atomoxetine to determine whether use
was associated with a greater risk of sudden death [63].
In 18,637 patient-years, six of the seven deaths were
determined to not be cases of sudden death, and one
death was of indeterminate cause. Compared to a refer-
ence rate of sudden death, the investigators did not find
a significantly increased risk of sudden death associated
with use of these medications.
Gould et al. conducted a case–control study of 564
cases of sudden death among youth 7 to 19 years old,
matched with 564 deceased passenger victims in motor
vehicle accidents. Stimulant use (amphetamine, dex-
troamphetamine, methamphetamine, methylphenidate)
was associated with increased odds of sudden death
(odds ratio = 7.4; 95% CI 1.4 to 74.9) [64].
Schelleman et al. (2011) studied youth 3 to 17 years
(n = 241,417), derived from a 5-state Medicaid database
and a 14-state health insurance database [65]. Hazard
ratios for incident exposure to stimulants (ampheta-
mines, atomoxetine, methylphenidate, or combination
therapy) compared to non-exposure were not signifi-
cantly elevated for primary outcomes of sudden death/
ventricular arrhythmia, stroke, myocardial infarction,
and composite stroke/myocardial infarction. Cardiovas-
cular outcomes were validated via medical records and
independent adjudication. However, only 48% of
requested records were obtained, and the adjudicators
were not reported as blinded. In secondary analyses
using claims-based outcomes (not validated) and preva-
lent (i.e. not incident) stimulant use, significant associa-
tions were found between sudden death/ventricular
arrhythmia and methylphenidate, atomoxetine, and any
ADHD medication.
Recently in 2011, Cooper et al. conducted a retrospect-
ive matched cohort study of children and young adults 2
to 24 years (n = 1,200,438) using Medicaid (Tennessee
and Washington), health insurance, state death certifi-
cates, and the National Death Index [66]. Current use of
ADHD medications was not significantly associated with
increased risk for serious cardiovascular events (sudden
Table 1 Population-Based Observational Studies of Prescription Stimulants and Adverse Cardiovascular Events
Year Author Study-Type/Drugs Data Source Population Independent
Variable








Florida Medicaid 3 to 20 years old with





1) Cardiac Death Cox regression No increased risk of cardiac
death or hospitalizations.
Observed 20% increase in
hazard for CV ER visits with











Florida Medicaid 3 to 20 years old with
diagnosis of ADHD
(52,783 person-years)

















18 years or older,
atomoxetine initiators
(n = 21,606) matched to
“ADHD medication”









No increased risk of CVA or TIA
with atomoxetine compared to
stimulants. Increased risk of TIA
with ADHD medication
compared to general
population (hazard ratio 3.44,










UK General Practice Research
Database
2 to 21 years old
(18,637 person-years)
Ever used Sudden death Incident rate ratio,
standardized mortality
ratio
No increased risk of sudden
death with stimulant and
atomoxetine use.






State vital statistics offices 7 to 19 years old,
sudden death
associated with
stimulant use (n = 926)
versus matched controls





Sudden death Logistic regression
analysis of matched pairs
Increased risk of sudden death
associated with stimulant use
(odds ratio 7.4, 95% confidence








Medicaid (5 states) and
health insurance database
(HealthCore)










difference in rates of outcomes





























No increased risk of serious
cardiovascular events for
current users (adjusted hazard
ratio 0.75, 95% confidence















































state death records, National
Death Index




















No increased risk of serious
cardiovascular events (MI/SCD/
stroke) for current users
compared to nonusers










Medicaid (5 states) and
health insurance database
(HealthCore)
18 years and older
methylphenidate users
(n = 43,999) matched to








age and data source;
propensity scoring as
secondary analysis
Increased risk of sudden death
or ventricular arrhythmia for
current users (adjusted hazard
ratio 1.84, 95% confidence
interval 1.33 to 2.55). No















6 to 21 years old with
ADHD and non know
cardiovascular risk
factors, treated with
stimulants (n = 89,031)
or not treated with














adjusted for age, days
from index diagnosis,
and propensity score
No analysis for severe
cardiovascular events was
performed due to only one
incident event in the entire
cohort. For less severe
cardiovascular events, there
was no increased risk
associated with stimulant use
compared to nonuse (adjusted





























Westover and Halm BMC Cardiovascular Disorders 2012, 12:41 Page 6 of 10
http://www.biomedcentral.com/1471-2261/12/41death, stroke, and myocardial infarction). Additional sec-
ondary analyses, with adjustments to inclusion criteria
and independent and dependent variables did not find a
significant relationship between ADHD medication use
and cardiovascular events. Analyses were adjusted for
baseline and time-varying covariates as well as site-spe-
cific propensity scores. The study benefitted from review
of medical records (79% availability) to perform end-
point validation [67].
Olfson et al. in 2012 studied 6 to 21 year olds
(n = 171,126) with ADHD and no known cardiovascular
risk factors, comparing stimulant users to nonusers [68].
The investigators intended to evaluate the risk of “severe
cardiovascular events” which included sudden death,
stroke, acute myocardial infarction, and respiratory ar-
rest. But only one incident event in the entire cohort
was discovered and no analysis was conducted due to
lack of power. The risk of “less severe cardiovascular
events” among persons with ADHD—comprising angina
pectoris, cardiac dysrhythmias, and transient cerebral is-
chemia—was not significantly different between stimu-
lant users and nonusers.
Adults
Holick et al.’s population-based study of adults 18 years
and older (adults ≥ 65 years old were included) compared
use of atomoxetine (a non-stimulant used in the treat-
ment of ADHD that is associated with increases in blood
pressure [69]; n = 21,606) to use of stimulant ADHD
medications (n = 21,606) [70]. Propensity scoring was
used to match atomoxetine and prescription stimulant
users. Use of atomoxetine was not associated with a ei-
ther a greater risk of stroke or transient ischemic attack
(TIA), compared to stimulant ADHD medications. In a
secondary analysis, atomoxetine and stimulant users,
matched to a general population cohort (n = 42,993), had
a significantly increased risk of TIA, but not stroke.
The study by Habel et al. represents the largest and
most comprehensive study of ADHD medications and
cardiovascular outcomes in adults to date (n = 443,198)
[71]. In this retrospective cohort study of adults 25
through 64 years old, each ADHD medication user was
matched to two nonusers. Medical charts, autopsy
reports and death certificates were obtained and adjudi-
cated for myocardial infarction (MI), sudden cardiac
death (SCD), and stroke outcomes where available. Ad-
justment for confounding included the use of a cardio-
vascular risk score (CRS), which summarized
cardiovascular risk factors. Unexpectedly, current use of
ADHD medications compared to nonuse was signifi-
cantly protective against serious cardiovascular events
(MI, SCD, or stroke; adjusted rate ratio 0.83, 95% CI,
0.72-0.96). The authors submitted a more detailed report
to the AHRQ, using only MI and SCD as outcomes, withthe same conclusion that the results did not support an
association between ADHD medication use and the risk
of MI and SCD [72].
The most recent study of adults (18 years and older),
by Schelleman et al. (2012), matched methylphenidate
users (n = 43,999) to nonusers (n = 175,955) and found
an increased risk of sudden death or ventricular
arrhythmia among users (adjusted hazard ratio 1.84, 95%
CI 1.33 to 2.55) [73]. No statistically significant differ-
ence in risk was found for stroke, myocardial infarction,
and a combined endpoint of stroke/myocardial infarc-
tion. In a secondary analysis, the risk of all-cause death
was significantly increased for methylphenidate users
compared to nonusers (adjusted hazard ratio 2.38, 95%
CI 2.20 to 2.56).
Discussion
Six out of seven studies in children and adolescents did
not show an increased risk of adverse cardiovascular
events (Table 1). Because the incidence of cardiovascular
events in children is low, the power needed to detect an
association between prescription stimulants and events
is extraordinarily high, leading to an increased likelihood
of a false negative outcome (type II error). The study
among the seven with the most power, by Cooper et al.
(n = 1,200,438), could not rule out a doubling of risk due
to the low incidence of serious cardiovascular events
(n = 81) in those 2 to 24 years old. Lack of statistical
power was an issue in other studies. Winterstein et al.
stated that 16 times more person-years would have been
required for their study to detect a doubling of the haz-
ard ratio [61]. The Schelleman et al. study (2011) found
no validated cases of ADHD-associated stroke and myo-
cardial infarction, strongly suggesting that the study was
under-powered. Likewise Olfson et al. found no severe
cardiovascular events in the study cohort. The study by
McCarthy et al. was also underpowered. There were
other limitations in the studies of children and adoles-
cents. The study by Gould et al., the only one to find an
association between prescription stimulants and adverse
cardiovascular outcomes in children and adolescents,
was unable match on race and geographical region, both
of which may have confounded the association. Add-
itionally, exposure to prescription stimulants was not
derived from pharmacy data, but rather from infor-
mants, medical records, toxicology findings, and death
certificates. Misclassification of exposure was also a con-
cern, if persons who were illicitly using street metham-
phetamine were classified as exposed to prescription
stimulants. In Schelleman et al.’s study (2011), analyses
were not adjusted for confounders, nor selection bias.
The three studies of adults had mixed findings, with
two of the studies showing a safety signal regarding pre-
scription stimulant use and cardiovascular outcomes.
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mic attack (TIA), but not stroke, among ADHD medica-
tion initiators compared to the general population in a
secondary analysis. However, unlike the primary analysis,
propensity scoring was not used to match the general
population cohort with the combined atomoxetine and
prescription stimulant use cohorts. A strength of this
study was that investigators attempted to corroborate
drug exposure and stroke/TIA outcomes in claims data
with medical records. In the Schelleman et al. study
(2012), methylphenidate use was associated with a 1.8-
fold increased risk of sudden death or ventricular
arrhythmia, but was not associated with increased risk
of stroke, myocardial infarction or combined stroke/
myocardial infarction. However, primary analyses were
adjusted for only age and data source. In post hoc ana-
lyses to account for confounding, propensity scores were
used and found similar results to the primary analyses,
with attenuated, but still significantly increased risks of
sudden death/ventricular arrhythmia and all-cause
death. The largest and most ambitious of the three stud-
ies of adults, by Habel et al., did not find an increased
risk of MI, sudden cardiac death, and stroke among
adults with short median exposure (median 0.33 years)
to ADHD medications. In fact, statistical results sug-
gested that ADHD medications were protective against
serious cardiovascular events [71] which the authors
acknowledged as “biologically implausible” [72]. With
survey data from Kaiser Permanente, external adjust-
ment methods were used to account for unmeasured
confounders among the entire cohort—including the
Tennessee Medicaid population which was sicker and
used ADHD medications for shorter periods of time on
average [72]. ADHD medication users were more edu-
cated and less likely to be black or Hispanic, leading the
investigators to state that the true estimate of the
adjusted risk ratio was likely higher but was masked due
to healthy user bias. In general the study population had
a low rate of cardiovascular risk factors. A strength of
this study included the numerous sensitivity analyses
that were performed, including that of new users,
current users versus remote users, and the construction
of a propensity score using variables included in the car-
diovascular risk score. These analyses did not suggest a
significant association between prescription stimulant
use and adverse cardiovascular outcomes. Although the
authors had 80% power to detect a rate ratio of 1.23 for
the primary analysis (current use versus nonuse), they
concluded that “a modestly elevated risk cannot be ruled
out, given limited power and a lack of complete informa-
tion on some potentially important risk factors and
other factors related to use of these medications.” The
study could not make any conclusions about the elderly,
as patients 65 years or older were not analyzed.Considerations for future studies: Methodological
challenges and proposed strategies
In the following section, we summarize the main meth-
odological challenges and outline considerations and
strategies for future studies. Low Absolute Rate of Car-
diovascular Events. Randomized clinical trials (RCTs)
are not feasible because of the low incidence rate of
stroke, acute myocardial infarction and cardiovascular
death, the need for very large numbers of patients, and
ethical concerns. Due to power considerations, future
work will need to rely on very large population-based
cohorts. Hard Clinical Outcomes. Future investigations
should be designed with hard clinical endpoints such as
death, myocardial infarction, and stroke as the primary
outcomes of interest. While prior literature has demon-
strated that small increases in blood pressure lead to
increased cardiovascular morbidity and mortality on a
population-basis [45], there is no proven association be-
tween stimulant-induced soft endpoints (e.g. increases in
blood pressure and heart rate) and hard cardiovascular
endpoints. Study Populations. Because the baseline
rates of sudden death, stroke, and myocardial infarction
in children are so low, increases in risk may not have a
large absolute impact. However in adults a modest in-
crease in risk could have significant clinical impact. Thus
an important strategy is to use an enriched population,
such as older adults, as greater than 80% of deaths due
to heart disease occur in those 65 years or older [74].
Measurement of Prescription Stimulant Use. The re-
lationship of time and dose of stimulants to the risk of
adverse cardiovascular events is unknown. It may be that
there are both acute and chronic risks with prescription
stimulant use. It stands to reason that a higher dose of
stimulants incurs more risk than a lower dose, but this
has not been proven [27]. Sensitivity analyses, where
modeling of use is varied, can help address this problem.
Confounders/Selection Bias/Control Groups.
Accounting for confounding and selection bias is the
greatest challenge for observational studies seeking to
study stimulants and the risk of cardiovascular events.
Confounding. Observational studies attempt to account
for confounding by including known confounders as
covariates in a multivariate analysis. Of particular con-
cern is confounding by indication, when a variable is
present in the non-exposed, but also an indication for
the exposure of interest (e.g. treatment of obesity with
prescription stimulants). Confounding by contraindica-
tion, where a patient avoids treatment due a contraindi-
cation, is also a potential problem. One way to address
confounding by indication or contraindication is to limit
the study population, by excluding persons with the
problematic indication(s). But this comes at the expense
of generalizability. Selection Bias. Persons that use pre-
scription amphetamines differ in important ways from
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these ways are known and measured, and can normally
be adjusted for in an analysis, such as comorbid medical
risk factors for cardiovascular events. But groups differ
in ways that are unmeasured. These unmeasured factors
are known in some cases (e.g. poor diet), and unknown
in others. Propensity scoring and instrumental variable
techniques are two more sophisticated statistical
approaches used to adjust for biases in observational
data. To date, five studies have used propensity scoring
[66,68,70,71,73]. Studies that do not account for selec-
tion bias are extremely difficult to interpret, as it
becomes unclear whether the risk is due to the inde-
pendent variable (prescription stimulant use), or the dif-
ferences in the populations that are compared. Even
with studies that do use propensity scoring, such as the
study by Habel et al., it can be difficult to determine
whether such techniques adequately accounted for un-
measured confounders. For example, inability of these
techniques to fully control for healthy user effects prob-
ably explains why Habel et al. found a lower risk-
adjusted rate of adverse cardiovascular events among sti-
mulants users. Use of propensity scoring and instrument
variables offers the promise of adjusting for selection
biases. As the ability to control for confounding and se-
lection bias increases, so does the confidence in the
results of such studies.Conclusions
Seven of the ten studies included in this systematic re-
view did not find an association between prescription
stimulant use and adverse cardiovascular outcomes. Six
of the seven studies of children and adolescents did not
find an association between prescription stimulant use
and adverse cardiovascular outcomes. Low incidence of
adverse cardiovascular outcomes among children and
adolescents in the general population hampered these
studies. In adults, however, a safety signal—prescription
stimulant use associated with adverse cardiovascular
outcomes—was demonstrated in two of three studies. Of
primary concern in these studies were problems of con-
founding and selection bias. Future studies must, in par-
ticular, address these issue. Studies of at-risk
populations, including the elderly and those with a high
burden of cardiovascular disease are needed as well.Competing interests
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